Full-Time

Chemical Engineering Senior Scientist

Updated on 3/15/2025

Vertex Pharmaceuticals

Vertex Pharmaceuticals

1,001-5,000 employees

Develops medicines for serious diseases

Compensation Overview

$123.2k - $184.7kAnnually

+ Bonus + Equity Awards

Senior, Expert

Company Does Not Provide H1B Sponsorship

Boston, MA, USA

This is an on-site designated role requiring five days per week in the office.

Category
Biology Lab & Research
Biology & Biotech
Required Skills
Data Analysis
Requirements
  • Knowledge of peptide and oligonucleotide synthesis, optimization, and isolation.
  • Hand-on experience with solid-phase automated synthesizers is preferred.
  • Experience developing and scaling-up solid phase and liquid phase chemistry and purification of resulting product streams.
  • Familiarity with reversed phase chromatography, ion exchange chromatography, size exclusion chromatography and other purification techniques.
  • Familiarity with high-resolution mass spectrometry and other medium size molecule characterization techniques.
  • A demonstrated understanding and working knowledge of chemistry and chemical engineering fundamentals including applied kinetics, thermodynamics, and transport phenomena.
  • Knowledge and experience in synthetic drug substance process development, process scale-up, troubleshooting, and optimization.
  • Familiarity with statistical design of experiments, QbD concepts, and common physical property and process modeling tools.
  • Ability to successfully interact and collaborate within an interdisciplinary team environment comprised of organic chemists, analytical chemists, project team members, and manufacturing personnel.
  • Proven communication (verbal and written) and interpersonal skills.
Responsibilities
  • Apply engineering principles to design and optimize drug substance manufacturing processes for the synthesis and purification of small molecules, oligonucleotides, and synthetically-derived peptides using both established and novel technologies.
  • Independently problem-solve in the laboratory setting to overcome synthetic, purification, and characterization challenges and develop/improve process workflows.
  • Support drug substance process development via laboratory development, pilot plant scale-up, drug supply preparation, and technology transfer to contract manufacturing organizations.
  • Manage relationships with external CRO/CMO partners.
  • Independently develop creative solutions to overcome obstacles during development.
  • Make use of state-of-the-art experimental, monitoring, and modeling approaches and/or data analyses for the evaluation and understanding of engineering unit operations--including reactions, purification, and isolation technologies.
  • Values teamwork and collaboration to solve problems and design strategies.
Desired Qualifications
  • Hand-on experience with solid-phase automated synthesizers is preferred.
Vertex Pharmaceuticals

Vertex Pharmaceuticals

View

Vertex Pharmaceuticals develops medicines for serious diseases, focusing on conditions like cystic fibrosis. The company conducts extensive research and development to create new drugs, often collaborating with other biotech firms to enhance its therapeutic offerings. One of its notable products is ivacaftor, which has shown effectiveness in treating cystic fibrosis. Vertex differentiates itself from competitors through its commitment to scientific innovation and strategic partnerships that expand its research capabilities. The goal of Vertex Pharmaceuticals is to improve the quality of life for patients with severe and life-threatening conditions by bringing effective treatments to market.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1989

Simplify Jobs

Simplify's Take

What believers are saying

  • Vertex's partnership with Orna enhances its gene therapy capabilities.
  • Increased investments indicate strong investor confidence in Vertex's growth potential.
  • Vertex's global expansion includes a patient assistance program for Trikafta in South Africa.

What critics are saying

  • Vertex is under investigation for potential securities law violations.
  • Mixed Phase II results for suzetrigine may delay its development.
  • The $1.07 billion Orna partnership could strain resources if unsuccessful.

What makes Vertex Pharmaceuticals unique

  • Vertex focuses on transformative medicines for serious diseases, like cystic fibrosis.
  • The company invests heavily in R&D and strategic biotech partnerships.
  • Vertex's innovative gene-editing therapies target sickle cell disease and beta thalassemia.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Company News

MarketBeat
Feb 14th, 2025
JSF Financial LLC Invests $751,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

JSF Financial LLC invests $751,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

MarketBeat
Jan 17th, 2025
Channel Wealth LLC Invests $716,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Channel Wealth LLC invests $716,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Zenopa
Jan 8th, 2025
Vertex and Orna Partner for Innovative Gene Therapy Solutions

In a significant advancement for the biopharma industry, Vertex Pharmaceuticals has announced a partnership with Orna Therapeutics to develop cutting-edge in vivo gene editing therapies targeting sickle cell disease and beta thalassaemia.

Pipeline Review
Jan 8th, 2025
Orna Therapeutics Establishes Strategic Collaboration with Vertex Pharmaceuticals to Develop Next Generation Approaches for Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)

We look forward to partnering with Vertex to develop transformative therapies for SCD and TDT, while simultaneously advancing our lead panCAR(TM) pipeline programs in autoimmune and oncology.

Precision Medicine Online
Jan 7th, 2025
Vertex Gains Rights to Orna Therapeutics' Drug Delivery Tech in $1.07B Deal

NEW YORK - Orna Therapeutics on Tuesday said it has inked a deal with Vertex Pharmaceuticals valued at more than $1.07 billion, in which Vertex will use its drug delivery technology to develop new gene-editing treatments for patients with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).